Characteristic | Mannitol 400 mg twice daily (n=207) | Control 50 mg twice daily (n=134) |
Age years | ||
Mean±sd | 28.3±8.75 | 28.8±8.46 |
Range | 18–56 | 18–53 |
Sex n (%) | ||
Male | 127 (61.4) | 71 (53.0) |
FEV1 % predicted | ||
Mean±sd | 59.8±15.6 | 58.4±15.8 |
Median (range) | 60.4 (26.4–92.6) | 54.2 (29.2–92.3) |
FEV1 L | ||
Mean±sd | 2.34 (0.80) | 2.16 (0.70) |
Median (range) | 2.20 (0.88–4.92) | 2.02 (1.03–4.12) |
BMI kg·m−2 | ||
Mean±sd | 22.6±3.73 | 22.1±3.25 |
Range | 15.3–44.6 | 14.9–33.4 |
rhDNase treatment n (%) | 122 (58.9) | 85 (63.4) |
Inhaled antibiotics n (%) | ||
Tobramycin | 72 (34.8) | 47 (35.1) |
Colistin | 62 (30.0) | 39 (29.1) |
Systemic antibodies n (%) | ||
Azithromcyin | 121 (58.5) | 75 (56.0) |
Drugs for obstructive airway disease n (%) | ||
Short-acting bronchodilator# | 201 (97.1) | 126 (94.0) |
Inhaled corticosteroids¶ | 135 (65.2) | 93 (69.4) |
BMI: body mass index; FEV1: forced expiration volume in 1 s. #: salbutamol (albuterol) or terbutaline; ¶: includes subjects on combination of an inhaled corticosteroid and a β agonist.